Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
MMP12-dependent myofibroblast formation contributes to nucleus pulposus fibrosis
Yi Sun, Wai-Kit Tam, Manyu Zhu, Qiuji Lu, Mengqi Yu, Yuching Hsu, Peng Chen, Peng Zhang, Minmin Lyu, Yongcan Huang, Zhaomin Zheng, Xintao Zhang, Victor Y. Leung
Yi Sun, Wai-Kit Tam, Manyu Zhu, Qiuji Lu, Mengqi Yu, Yuching Hsu, Peng Chen, Peng Zhang, Minmin Lyu, Yongcan Huang, Zhaomin Zheng, Xintao Zhang, Victor Y. Leung
View: Text | PDF
Research Article Bone biology Cell biology

MMP12-dependent myofibroblast formation contributes to nucleus pulposus fibrosis

  • Text
  • PDF
Abstract

Intervertebral disc degeneration (IDD) is associated with low back pain, a leading cause of disability worldwide. Fibrosis of nucleus pulposus (NP) is a principal component of IDD, featuring an accumulation of myofibroblast-like cells. Previous study indicates that matrix metalloproteinase 12 (MMP12) expression is upregulated in IDD, but its role remains largely unexplored. We here showed that TGF-β1 could promote myofibroblast-like differentiation of human NP cells along with an induction of MMP12 expression. Intriguingly, MMP12 knockdown not only ameliorated the myofibroblastic phenotype but also increased chondrogenic marker expression. Transcriptome analysis revealed that the MMP12-mediated acquisition of myofibroblast phenotype was coupled to processes related to fibroblast activation and osteogenesis and to pathways mediated by MAPK and Wnt signaling. Injury induced mouse IDD showed NP fibrosis with marked increase of collagen deposition and αSMA-expressing cells. In contrast, MMP12-KO mice exhibited largely reduced collagen I and III but increased collagen II and aggrecan deposition, indicating an inhibition of NP fibrosis along with an enhanced cartilaginous matrix remodeling. Consistently, an increase of SOX9+ and CNMD+ but decrease of αSMA+ NP cells was found in the KO. Altogether, our findings suggest a pivotal role of MMP12 in myofibroblast generation, thereby regulating NP fibrosis in IDD.

Authors

Yi Sun, Wai-Kit Tam, Manyu Zhu, Qiuji Lu, Mengqi Yu, Yuching Hsu, Peng Chen, Peng Zhang, Minmin Lyu, Yongcan Huang, Zhaomin Zheng, Xintao Zhang, Victor Y. Leung

×

Figure 3

MMP12-dependent myofibroblast differentiation of human NPC.

Options: View larger image (or click on image) Download as PowerPoint
MMP12-dependent myofibroblast differentiation of human NPC.
(A) Immunobl...
(A) Immunoblotting and densitometric quantification of MMP12 and αSMA expression in TGF-β1–induced myofibroblast differentiation of nNPC and human dNPC (n = 3). GAPDH is used as a loading control. (B) Immunofluorescence of MMP12. Scale bar: 100 μm. (C and D) RT-PCR and immunoblotting for MMP12, myofibroblastic markers αSMA (ACTA2), collagen I (COL1A1) and III (COL3A1), integrin subunit β6 (ITGB6), fibrotic regulator cysteine rich protein angiogenic inducer 61 (CYR61), and chondrogenic factor SOX9 in dNPC treated with TGF-β1 and transfected with MMP12 siRNA (siMMP12). Semiquantitative analysis showing fold changes from nontreated NPC (n = 5 biological replicates/group). *P < 0.05, **P < 0.01 determined by Brown-Forsythe and Welch ANOVA with Dunnett’s T3 test for RT-PCR and repeated measures 2-way ANOVA with Bonferroni’s multiple-comparison test for protein quantification; #P < 0.05, ##P < 0.05, ###P < 0.001 calculated by comparison between the scramble/TGF-β1 and the siMMP12/TGF-β1 groups.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts